AU1540599A - Human thyroid protein zsig45 and dna encoding same - Google Patents

Info

Publication number

AU1540599A

AU1540599A AU15405/99A AU1540599A AU1540599A AU 1540599 A AU1540599 A AU 1540599A AU 15405/99 A AU15405/99 A AU 15405/99A AU 1540599 A AU1540599 A AU 1540599A AU 1540599 A AU1540599 A AU 1540599A

Authority

AU

Australia

Prior art keywords

zsig45

amino acid

seq

polypeptide

sequence

Prior art date

1997-12-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000623 proteins and genes Proteins 0.000 title description 152
• 102000004169 proteins and genes Human genes 0.000 title description 90
• 210000001685 thyroid gland Anatomy 0.000 title description 55
• 241000282414 Homo sapiens Species 0.000 title description 40
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 370
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 349
• 229920001184 polypeptide Polymers 0.000 claims description 334
• 210000004027 cell Anatomy 0.000 claims description 241
• 238000000034 method Methods 0.000 claims description 133
• 150000001413 amino acids Chemical class 0.000 claims description 104
• 102000040430 polynucleotide Human genes 0.000 claims description 76
• 108091033319 polynucleotide Proteins 0.000 claims description 76
• 239000002157 polynucleotide Substances 0.000 claims description 76
• 230000000694 effects Effects 0.000 claims description 66
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
• 239000002773 nucleotide Substances 0.000 claims description 42
• 125000003729 nucleotide group Chemical group 0.000 claims description 42
• 125000000539 amino acid group Chemical group 0.000 claims description 36
• 239000005557 antagonist Substances 0.000 claims description 34
• 238000012360 testing method Methods 0.000 claims description 31
• 230000000295 complement effect Effects 0.000 claims description 28
• 230000003248 secreting effect Effects 0.000 claims description 28
• 239000000556 agonist Substances 0.000 claims description 25
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 23
• 108020001507 fusion proteins Proteins 0.000 claims description 23
• 102000037865 fusion proteins Human genes 0.000 claims description 23
• 241001465754 Metazoa Species 0.000 claims description 22
• 239000013604 expression vector Substances 0.000 claims description 20
• 238000013518 transcription Methods 0.000 claims description 14
• 230000035897 transcription Effects 0.000 claims description 14
• 238000012258 culturing Methods 0.000 claims description 12
• 239000002253 acid Substances 0.000 claims description 11
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
• 230000004044 response Effects 0.000 claims description 7
• 108700008625 Reporter Genes Proteins 0.000 claims description 6
• 238000004166 bioassay Methods 0.000 claims description 6
• 238000010256 biochemical assay Methods 0.000 claims description 4
• 230000004640 cellular pathway Effects 0.000 claims description 4
• 210000004748 cultured cell Anatomy 0.000 claims description 4
• 230000028993 immune response Effects 0.000 claims description 4
• 230000004952 protein activity Effects 0.000 claims description 4
• 108020004414 DNA Proteins 0.000 description 98
• 235000018102 proteins Nutrition 0.000 description 87
• 235000001014 amino acid Nutrition 0.000 description 73
• 229940024606 amino acid Drugs 0.000 description 69
• 210000001519 tissue Anatomy 0.000 description 65
• 238000003556 assay Methods 0.000 description 61
• 230000014509 gene expression Effects 0.000 description 52
• 239000013598 vector Substances 0.000 description 37
• 108020004635 Complementary DNA Proteins 0.000 description 36
• 238000001727 in vivo Methods 0.000 description 36
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
• 102000005962 receptors Human genes 0.000 description 35
• 108020003175 receptors Proteins 0.000 description 35
• 238000010804 cDNA synthesis Methods 0.000 description 34
• 239000002299 complementary DNA Substances 0.000 description 34
• 238000011282 treatment Methods 0.000 description 30
• 201000010099 disease Diseases 0.000 description 29
• 239000012634 fragment Substances 0.000 description 29
• 241000699670 Mus sp. Species 0.000 description 27
• 241000700605 Viruses Species 0.000 description 25
• 230000027455 binding Effects 0.000 description 25
• 239000000523 sample Substances 0.000 description 24
• 230000004927 fusion Effects 0.000 description 22
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
• 108020004705 Codon Proteins 0.000 description 21
• 230000006870 function Effects 0.000 description 21
• 239000000499 gel Substances 0.000 description 21
• 239000013612 plasmid Substances 0.000 description 21
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 20
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
• 239000003446 ligand Substances 0.000 description 19
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
• 238000004458 analytical method Methods 0.000 description 18
• 210000002216 heart Anatomy 0.000 description 18
• 238000000338 in vitro Methods 0.000 description 18
• 238000004519 manufacturing process Methods 0.000 description 18
• 108020004999 messenger RNA Proteins 0.000 description 18
• 239000000243 solution Substances 0.000 description 18
• 241000894007 species Species 0.000 description 18
• 239000005495 thyroid hormone Substances 0.000 description 18
• 241001452677 Ogataea methanolica Species 0.000 description 17
• 238000006243 chemical reaction Methods 0.000 description 17
• 239000000203 mixture Substances 0.000 description 17
• 229940036555 thyroid hormone Drugs 0.000 description 17
• 206010061218 Inflammation Diseases 0.000 description 15
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
• 230000004054 inflammatory process Effects 0.000 description 15
• 239000002953 phosphate buffered saline Substances 0.000 description 15
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 description 14
• 210000000988 bone and bone Anatomy 0.000 description 14
• 238000000746 purification Methods 0.000 description 14
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
• 230000000692 anti-sense effect Effects 0.000 description 13
• 230000037361 pathway Effects 0.000 description 13
• 230000001817 pituitary effect Effects 0.000 description 13
• 241000700159 Rattus Species 0.000 description 12
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
• 230000008859 change Effects 0.000 description 12
• 230000004069 differentiation Effects 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
• 102000004877 Insulin Human genes 0.000 description 11
• 108090001061 Insulin Proteins 0.000 description 11
• 230000004913 activation Effects 0.000 description 11
• 229940098773 bovine serum albumin Drugs 0.000 description 11
• 150000001875 compounds Chemical class 0.000 description 11
• 229940125396 insulin Drugs 0.000 description 11
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 11
• 230000002265 prevention Effects 0.000 description 11
• 239000013615 primer Substances 0.000 description 11
• 238000012216 screening Methods 0.000 description 11
• 230000019491 signal transduction Effects 0.000 description 11
• 230000014616 translation Effects 0.000 description 11
• 241000701161 unidentified adenovirus Species 0.000 description 11
• 241000588724 Escherichia coli Species 0.000 description 10
• 108091034117 Oligonucleotide Proteins 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 230000036755 cellular response Effects 0.000 description 10
• 239000003814 drug Substances 0.000 description 10
• 229940088597 hormone Drugs 0.000 description 10
• 239000005556 hormone Substances 0.000 description 10
• 239000006166 lysate Substances 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 230000035755 proliferation Effects 0.000 description 10
• 230000028327 secretion Effects 0.000 description 10
• 238000001262 western blot Methods 0.000 description 10
• 108010001789 Calcitonin Receptors Proteins 0.000 description 9
• 102100038520 Calcitonin receptor Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• 108700026244 Open Reading Frames Proteins 0.000 description 9
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 9
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 9
• 238000010171 animal model Methods 0.000 description 9
• 210000004899 c-terminal region Anatomy 0.000 description 9
• 230000000747 cardiac effect Effects 0.000 description 9
• 238000010790 dilution Methods 0.000 description 9
• 239000012895 dilution Substances 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 210000002889 endothelial cell Anatomy 0.000 description 9
• 238000000855 fermentation Methods 0.000 description 9
• 230000004151 fermentation Effects 0.000 description 9
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 230000005855 radiation Effects 0.000 description 9
• 238000001890 transfection Methods 0.000 description 9
• 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 229920002684 Sepharose Polymers 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 210000004413 cardiac myocyte Anatomy 0.000 description 8
• 231100000433 cytotoxic Toxicity 0.000 description 8
• 230000001472 cytotoxic effect Effects 0.000 description 8
• 230000002950 deficient Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 238000004520 electroporation Methods 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 239000008103 glucose Substances 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 239000008194 pharmaceutical composition Substances 0.000 description 8
• 230000008685 targeting Effects 0.000 description 8
• 241000701447 unidentified baculovirus Species 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• 102000014914 Carrier Proteins Human genes 0.000 description 7
• 230000009471 action Effects 0.000 description 7
• 239000000427 antigen Substances 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 102000036639 antigens Human genes 0.000 description 7
• 108091008324 binding proteins Proteins 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
• 210000000349 chromosome Anatomy 0.000 description 7
• 210000001072 colon Anatomy 0.000 description 7
• 230000000120 cytopathologic effect Effects 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 230000002255 enzymatic effect Effects 0.000 description 7
• 210000003527 eukaryotic cell Anatomy 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 230000004217 heart function Effects 0.000 description 7
• 238000009396 hybridization Methods 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 210000004962 mammalian cell Anatomy 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 229960004452 methionine Drugs 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 210000000130 stem cell Anatomy 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 238000011830 transgenic mouse model Methods 0.000 description 7
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 6
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
• 241000238631 Hexapoda Species 0.000 description 6
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
• 241000699660 Mus musculus Species 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 230000002391 anti-complement effect Effects 0.000 description 6
• 108010008730 anticomplement Proteins 0.000 description 6
• 239000011324 bead Substances 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 230000006539 extracellular acidification Effects 0.000 description 6
• 230000004190 glucose uptake Effects 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 230000002503 metabolic effect Effects 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 230000011164 ossification Effects 0.000 description 6
• 210000000963 osteoblast Anatomy 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 239000011347 resin Substances 0.000 description 6
• 229920005989 resin Polymers 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 239000000758 substrate Substances 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 210000005253 yeast cell Anatomy 0.000 description 6
• 206010005949 Bone cancer Diseases 0.000 description 5
• 208000018084 Bone neoplasm Diseases 0.000 description 5
• 108091029865 Exogenous DNA Proteins 0.000 description 5
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 108090000862 Ion Channels Proteins 0.000 description 5
• 102000004310 Ion Channels Human genes 0.000 description 5
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 239000005089 Luciferase Substances 0.000 description 5
• 102000018697 Membrane Proteins Human genes 0.000 description 5
• 108010052285 Membrane Proteins Proteins 0.000 description 5
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
• 208000024799 Thyroid disease Diseases 0.000 description 5
• 102000011923 Thyrotropin Human genes 0.000 description 5
• 108010061174 Thyrotropin Proteins 0.000 description 5
• 208000027418 Wounds and injury Diseases 0.000 description 5
• 238000002835 absorbance Methods 0.000 description 5
• 210000001789 adipocyte Anatomy 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 230000003171 anti-complementary effect Effects 0.000 description 5
• 230000000840 anti-viral effect Effects 0.000 description 5
• 206010003246 arthritis Diseases 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 230000000905 extrathyroidal effect Effects 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 210000001035 gastrointestinal tract Anatomy 0.000 description 5
• 230000004110 gluconeogenesis Effects 0.000 description 5
• 230000004116 glycogenolysis Effects 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 206010020718 hyperplasia Diseases 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 208000027866 inflammatory disease Diseases 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 150000002500 ions Chemical class 0.000 description 5
• 238000002955 isolation Methods 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 230000007257 malfunction Effects 0.000 description 5
• 210000003622 mature neutrocyte Anatomy 0.000 description 5
• 230000004060 metabolic process Effects 0.000 description 5
• 229930182817 methionine Natural products 0.000 description 5
• 238000002703 mutagenesis Methods 0.000 description 5
• 231100000350 mutagenesis Toxicity 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000000770 proinflammatory effect Effects 0.000 description 5
• 230000008929 regeneration Effects 0.000 description 5
• 238000011069 regeneration method Methods 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 230000008439 repair process Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 230000035924 thermogenesis Effects 0.000 description 5
• 239000003053 toxin Substances 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 230000009466 transformation Effects 0.000 description 5
• 230000001131 transforming effect Effects 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 101710094503 Metallothionein-1 Proteins 0.000 description 4
• 241001529936 Murinae Species 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• 238000000636 Northern blotting Methods 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 description 4
• 108010007389 Trefoil Factors Proteins 0.000 description 4
• 102000007641 Trefoil Factors Human genes 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 230000011759 adipose tissue development Effects 0.000 description 4
• 239000011543 agarose gel Substances 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 230000000975 bioactive effect Effects 0.000 description 4
• 230000024279 bone resorption Effects 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000010828 elution Methods 0.000 description 4
• 239000003797 essential amino acid Substances 0.000 description 4
• 235000020776 essential amino acid Nutrition 0.000 description 4
• 210000002907 exocrine cell Anatomy 0.000 description 4
• 238000000605 extraction Methods 0.000 description 4
• 230000006377 glucose transport Effects 0.000 description 4
• 239000005090 green fluorescent protein Substances 0.000 description 4
• 210000002064 heart cell Anatomy 0.000 description 4
• 210000005003 heart tissue Anatomy 0.000 description 4
• 210000003917 human chromosome Anatomy 0.000 description 4
• 230000002209 hydrophobic effect Effects 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 238000011813 knockout mouse model Methods 0.000 description 4
• 229960003136 leucine Drugs 0.000 description 4
• 108020001756 ligand binding domains Proteins 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 230000004132 lipogenesis Effects 0.000 description 4
• 229920002521 macromolecule Polymers 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
• 230000007102 metabolic function Effects 0.000 description 4
• 230000002107 myocardial effect Effects 0.000 description 4
• 210000000107 myocyte Anatomy 0.000 description 4
• 230000009707 neogenesis Effects 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 210000000287 oocyte Anatomy 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• 238000001243 protein synthesis Methods 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 208000020084 Bone disease Diseases 0.000 description 3
• 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 3
• 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 3
• 102100035882 Catalase Human genes 0.000 description 3
• 108010053835 Catalase Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 230000006820 DNA synthesis Effects 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 206010020850 Hyperthyroidism Diseases 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 241000235648 Pichia Species 0.000 description 3
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108700005078 Synthetic Genes Proteins 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 229960000723 ampicillin Drugs 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• -1 antibodies Substances 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 230000002759 chromosomal effect Effects 0.000 description 3
• 230000004087 circulation Effects 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 238000004925 denaturation Methods 0.000 description 3
• 230000036425 denaturation Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000000502 dialysis Methods 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 108091005608 glycosylated proteins Proteins 0.000 description 3
• 102000035122 glycosylated proteins Human genes 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 208000019622 heart disease Diseases 0.000 description 3
• 238000002744 homologous recombination Methods 0.000 description 3
• 230000006801 homologous recombination Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 230000000968 intestinal effect Effects 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 210000005229 liver cell Anatomy 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
• 238000000520 microinjection Methods 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 210000001087 myotubule Anatomy 0.000 description 3
• 210000004412 neuroendocrine cell Anatomy 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 229960002748 norepinephrine Drugs 0.000 description 3
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
• 102000006255 nuclear receptors Human genes 0.000 description 3
• 108020004017 nuclear receptors Proteins 0.000 description 3
• 235000015097 nutrients Nutrition 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 210000001322 periplasm Anatomy 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000004224 protection Effects 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 108091008146 restriction endonucleases Proteins 0.000 description 3
• 210000002027 skeletal muscle Anatomy 0.000 description 3
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
• 229960002920 sorbitol Drugs 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000001971 thyroidal effect Effects 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 2
• DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 2
• VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 2
• KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
• XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 241000589156 Agrobacterium rhizogenes Species 0.000 description 2
• 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 208000006386 Bone Resorption Diseases 0.000 description 2
• 206010065687 Bone loss Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102000055006 Calcitonin Human genes 0.000 description 2
• 108060001064 Calcitonin Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 206010061005 Cardiac myxoma Diseases 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• 108700010070 Codon Usage Proteins 0.000 description 2
• 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 206010013883 Dwarfism Diseases 0.000 description 2
• 102000001301 EGF receptor Human genes 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
• 102100036509 Erythropoietin receptor Human genes 0.000 description 2
• 108091060211 Expressed sequence tag Proteins 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 108010067193 Formaldehyde transketolase Proteins 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 2
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102100020948 Growth hormone receptor Human genes 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 102000006354 HLA-DR Antigens Human genes 0.000 description 2
• 108010058597 HLA-DR Antigens Proteins 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
• 102000002265 Human Growth Hormone Human genes 0.000 description 2
• 108010000521 Human Growth Hormone Proteins 0.000 description 2
• 239000000854 Human Growth Hormone Substances 0.000 description 2
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 108010038452 Interleukin-3 Receptors Proteins 0.000 description 2
• 102000010790 Interleukin-3 Receptors Human genes 0.000 description 2
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 2
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
• 241000235058 Komagataella pastoris Species 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 102000016267 Leptin Human genes 0.000 description 2
• 108010092277 Leptin Proteins 0.000 description 2
• 239000006137 Luria-Bertani broth Substances 0.000 description 2
• 108091092878 Microsatellite Proteins 0.000 description 2
• 108091061960 Naked DNA Proteins 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 108020004485 Nonsense Codon Proteins 0.000 description 2
• 108091060545 Nonsense suppressor Proteins 0.000 description 2
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 108091008606 PDGF receptors Proteins 0.000 description 2
• 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 108091034057 RNA (poly(A)) Proteins 0.000 description 2
• 108091027981 Response element Proteins 0.000 description 2
• 241000235070 Saccharomyces Species 0.000 description 2
• 229920005654 Sephadex Polymers 0.000 description 2
• 239000012507 Sephadex™ Substances 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 108010068542 Somatotropin Receptors Proteins 0.000 description 2
• 241000256251 Spodoptera frugiperda Species 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
• 108091036066 Three prime untranslated region Proteins 0.000 description 2
• 241000795412 Thyriodes Species 0.000 description 2
• 108010034949 Thyroglobulin Proteins 0.000 description 2
• 102000009843 Thyroglobulin Human genes 0.000 description 2
• 102000003911 Thyrotropin Receptors Human genes 0.000 description 2
• 108090000253 Thyrotropin Receptors Proteins 0.000 description 2
• 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
• 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
• 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 235000015724 Trifolium pratense Nutrition 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
• 229960004373 acetylcholine Drugs 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 108060000200 adenylate cyclase Proteins 0.000 description 2
• 102000030621 adenylate cyclase Human genes 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 238000000246 agarose gel electrophoresis Methods 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• ROLZYTOAMYXLMF-UHFFFAOYSA-N amino(benzyl)carbamic acid Chemical compound OC(=O)N(N)CC1=CC=CC=C1 ROLZYTOAMYXLMF-UHFFFAOYSA-N 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 238000000137 annealing Methods 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 210000000709 aorta Anatomy 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 238000004820 blood count Methods 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000003491 cAMP production Effects 0.000 description 2
• 229960004015 calcitonin Drugs 0.000 description 2
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 229940041514 candida albicans extract Drugs 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 125000000837 carbohydrate group Chemical group 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000019522 cellular metabolic process Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 239000012501 chromatography medium Substances 0.000 description 2
• 231100000762 chronic effect Toxicity 0.000 description 2
• PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
• 238000012411 cloning technique Methods 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 229940095074 cyclic amp Drugs 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 230000001627 detrimental effect Effects 0.000 description 2
• 229960002086 dextran Drugs 0.000 description 2
• 230000001079 digestive effect Effects 0.000 description 2
• 230000000447 dimerizing effect Effects 0.000 description 2
• 208000007784 diverticulitis Diseases 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 238000005194 fractionation Methods 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 102000034356 gene-regulatory proteins Human genes 0.000 description 2
• 108091006104 gene-regulatory proteins Proteins 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 108010044853 histidine-rich proteins Proteins 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 208000003532 hypothyroidism Diseases 0.000 description 2
• 230000002989 hypothyroidism Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000013198 immunometric assay Methods 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 230000000415 inactivating effect Effects 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000004255 ion exchange chromatography Methods 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 210000003041 ligament Anatomy 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 239000006249 magnetic particle Substances 0.000 description 2
• 230000002175 menstrual effect Effects 0.000 description 2
• 238000006241 metabolic reaction Methods 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000000955 neuroendocrine Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 230000037434 nonsense mutation Effects 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 210000001778 pluripotent stem cell Anatomy 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 239000004417 polycarbonate Substances 0.000 description 2
• 229920000515 polycarbonate Polymers 0.000 description 2
• 229920002704 polyhistidine Polymers 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 230000003334 potential effect Effects 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 230000037452 priming Effects 0.000 description 2
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 238000002821 scintillation proximity assay Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 208000037905 systemic hypertension Diseases 0.000 description 2
• 230000028016 temperature homeostasis Effects 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 229960002175 thyroglobulin Drugs 0.000 description 2
• 230000006016 thyroid dysfunction Effects 0.000 description 2
• 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 238000012384 transportation and delivery Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• 108700026220 vif Genes Proteins 0.000 description 2
• 230000029812 viral genome replication Effects 0.000 description 2
• 210000002845 virion Anatomy 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 239000012138 yeast extract Substances 0.000 description 2
• UJXJZOCXEZPHIE-YFKPBYRVSA-N (2s)-2-(2-hydroxyethylamino)-4-sulfanylbutanoic acid Chemical compound OCCN[C@H](C(O)=O)CCS UJXJZOCXEZPHIE-YFKPBYRVSA-N 0.000 description 1
• KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
• JQFLYFRHDIHZFZ-RXMQYKEDSA-N (2s)-3,3-dimethylpyrrolidine-2-carboxylic acid Chemical compound CC1(C)CCN[C@@H]1C(O)=O JQFLYFRHDIHZFZ-RXMQYKEDSA-N 0.000 description 1
• CNPSFBUUYIVHAP-AKGZTFGVSA-N (2s)-3-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-AKGZTFGVSA-N 0.000 description 1
• FXGZFWDCXQRZKI-VKHMYHEASA-N (2s)-5-amino-2-nitramido-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)N[N+]([O-])=O FXGZFWDCXQRZKI-VKHMYHEASA-N 0.000 description 1
• CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 1
• CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
• DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
• OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• XEVFXAFXZZYFSX-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-4-carboxylic acid Chemical compound C1C2CC1(C(=O)O)NC2 XEVFXAFXZZYFSX-UHFFFAOYSA-N 0.000 description 1
• GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 101150096273 ADE2 gene Proteins 0.000 description 1
• WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 241000228431 Acremonium chrysogenum Species 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
• 241000222128 Candida maltosa Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 206010048964 Carotid artery occlusion Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000218645 Cedrus Species 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 208000031404 Chromosome Aberrations Diseases 0.000 description 1
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010069729 Collateral circulation Diseases 0.000 description 1
• 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 208000001778 Coronary Occlusion Diseases 0.000 description 1
• 206010011086 Coronary artery occlusion Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 108700029231 Developmental Genes Proteins 0.000 description 1
• 208000008960 Diabetic foot Diseases 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
• 241001635598 Enicostema Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 108010053070 Glutathione Disulfide Proteins 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
• 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
• 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 1
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 201000002980 Hyperparathyroidism Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• 102000011845 Iodide peroxidase Human genes 0.000 description 1
• 108010036012 Iodide peroxidase Proteins 0.000 description 1
• 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• 241000235650 Kluyveromyces marxianus Species 0.000 description 1
• 238000012313 Kruskal-Wallis test Methods 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• 239000004395 L-leucine Substances 0.000 description 1
• 235000019454 L-leucine Nutrition 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
• DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
• KKJQZEWNZXRJFG-UHFFFAOYSA-N L-trans-4-Methyl-2-pyrrolidinecarboxylic acid Chemical compound CC1CNC(C(O)=O)C1 KKJQZEWNZXRJFG-UHFFFAOYSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 241000270322 Lepidosauria Species 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 208000032376 Lung infection Diseases 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
• 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 102100030856 Myoglobin Human genes 0.000 description 1
• 108010062374 Myoglobin Proteins 0.000 description 1
• 241001477931 Mythimna unipuncta Species 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 229920002274 Nalgene Polymers 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 102000019040 Nuclear Antigens Human genes 0.000 description 1
• 108010051791 Nuclear Antigens Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 206010030247 Oestrogen deficiency Diseases 0.000 description 1
• 241000320412 Ogataea angusta Species 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 101150029183 PEP4 gene Proteins 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 208000016222 Pancreatic disease Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 239000001888 Peptone Substances 0.000 description 1
• 108010080698 Peptones Proteins 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 108010019653 Pwo polymerase Proteins 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• 108091006296 SLC2A1 Proteins 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 239000008049 TAE buffer Substances 0.000 description 1
• 102000002933 Thioredoxin Human genes 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 206010043515 Throat cancer Diseases 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 241000255993 Trichoplusia ni Species 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102400000757 Ubiquitin Human genes 0.000 description 1
• 244000301083 Ustilago maydis Species 0.000 description 1
• 235000015919 Ustilago maydis Nutrition 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 108070000030 Viral receptors Proteins 0.000 description 1
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• 241000269368 Xenopus laevis Species 0.000 description 1
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
• PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000005273 aeration Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000000689 aminoacylating effect Effects 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 231100001075 aneuploidy Toxicity 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 108010062796 arginyllysine Proteins 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 210000001992 atrioventricular node Anatomy 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 239000007640 basal medium Substances 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000009141 biological interaction Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 239000007844 bleaching agent Substances 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000004221 bone function Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 201000006491 bone marrow cancer Diseases 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 230000007883 bronchodilation Effects 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 239000001354 calcium citrate Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 210000001054 cardiac fibroblast Anatomy 0.000 description 1
• 210000000803 cardiac myoblast Anatomy 0.000 description 1
• 230000009084 cardiovascular function Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 108091008394 cellulose binding proteins Proteins 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 230000035572 chemosensitivity Effects 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
• 231100000005 chromosome aberration Toxicity 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 210000003748 coronary sinus Anatomy 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000032459 dedifferentiation Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000005831 deiodination reaction Methods 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 238000002003 electron diffraction Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 238000013171 endarterectomy Methods 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 150000002118 epoxides Chemical class 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 235000020774 essential nutrients Nutrition 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 238000010228 ex vivo assay Methods 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 230000004545 gene duplication Effects 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• 230000002039 glucoregulatory effect Effects 0.000 description 1
• 230000009229 glucose formation Effects 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 150000002337 glycosamines Chemical class 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 230000036732 histological change Effects 0.000 description 1
• 231100000508 hormonal effect Toxicity 0.000 description 1
• 102000054751 human RUNX1T1 Human genes 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 230000001127 hyperphagic effect Effects 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
• 230000001184 hypocalcaemic effect Effects 0.000 description 1
• 230000002806 hypometabolic effect Effects 0.000 description 1
• 239000000960 hypophysis hormone Substances 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000012308 immunohistochemistry method Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 150000004001 inositols Chemical class 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 230000037427 ion transport Effects 0.000 description 1
• GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 238000012317 liver biopsy Methods 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 230000031852 maintenance of location in cell Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 238000007431 microscopic evaluation Methods 0.000 description 1
• 238000010232 migration assay Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 210000003098 myoblast Anatomy 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 230000001818 nuclear effect Effects 0.000 description 1
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 235000018343 nutrient deficiency Nutrition 0.000 description 1
• 235000021231 nutrient uptake Nutrition 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 239000000082 organ preservation Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 208000005368 osteomalacia Diseases 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 238000012402 patch clamp technique Methods 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 229950000964 pepstatin Drugs 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 235000019319 peptone Nutrition 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 238000005222 photoaffinity labeling Methods 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 229940076788 pyruvate Drugs 0.000 description 1
• 238000003156 radioimmunoprecipitation Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 239000001044 red dye Substances 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 210000002955 secretory cell Anatomy 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 230000037432 silent mutation Effects 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000001013 sinoatrial node Anatomy 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000004683 skeletal myoblast Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000000638 solvent extraction Methods 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000012134 supernatant fraction Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 102000004217 thyroid hormone receptors Human genes 0.000 description 1
• 108090000721 thyroid hormone receptors Proteins 0.000 description 1
• 208000013076 thyroid tumor Diseases 0.000 description 1
• 208000005057 thyrotoxicosis Diseases 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• 239000012137 tryptone Substances 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 239000013026 undiluted sample Substances 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1